Grow Your Wealth
with Mutual Funds
Nippon India Pharma Fund-growth
Equity
Mid Cap
Very High Risk
Latest AUM
₹ 7,898.2 Cr.
NAV as on 27 jul, 2026
₹ 563.86
+20.58%
3 years annulised
This Fund
Fund Details
Fund Names
Nippon India Pharma Fund-growth
Inception Date
05 Jun 2004
Lock In
No Lock-in
SIP Minimum Investment amount
₹100
SWP Minimum Investment amount
₹500
STP Minimum Investment amount
₹100
Risk
Principal at very high risk
Category Average Annual Returns
6.04
Portfolio Composition Analysis
Equity
97.64%
Debt
0.01%
Cash
2.35%
Portfolio Updated on: 10 Jul, 2026
Sector Allocations
Equity
Healthcare
Portfolio Updated on: 27 jul, 2026
Top 10 Holdings
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 1.00% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.55% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.92% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.08% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.02% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.67% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.67% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.67% |
Debt & Credit Risk Analysis
| Alpha | -0.98% |
| Beta | 0.91% |
| Sharpe Ratio | 0.96% |
| Standard Deviation | 15.71% |
Returns Analysis
| Tenure | Absolute | Annualised | Category Average |
|---|---|---|---|
| 3 Months | 8.92% | NA | 6.12% |
| 6 Months | 15.97% | NA | 12.92% |
| 9 Months | 9.86% | NA | 4.47% |
| 1 Year | 6.41% | 6.41% | 6.04% |
| 2 Years | 16.79% | 8.07% | 24.93% |
| 3 Years | 65.48% | 18.28% | 25.71% |
| 5 Years | 84.16% | 12.99% | 19.91% |
| 7 Years | 296.08% | 21.73% | NA |
| 10 Years | 301.05% | 14.90% | 12.78% |
Nippon India Pharma Fund-growth is one Equity mutual fund offered by Nippon India Mutual Fund. Launched on 05 Jun 2004, the fund aims Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies. It manages assets worth ₹7,898.2 crore as on Tue Mar 31, 2026. The expense ratio stands at 1.82%.
Sailesh Raj Bhan has experience Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Top Performing Mutual Funds
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More Funds from Nippon India Mutual Fund
| Fund name | |||||||
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-idcw | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Nifty Pharma Etf-growth | 1,247.9 | +4.08% | +12.23% | +19.56% | +14.83% | +20.80% | +13.69% |
growth is based on 1-month returns of the funds
Top Mutual Funds
| Fund name | |||||||
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-growth | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund-idcw | 7,898.2 | +2.37% | +8.92% | +15.97% | +6.41% | +18.28% | +12.99% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| Nippon India Pharma Fund Direct-idcw | 7,898.2 | +2.44% | +9.15% | +16.47% | +7.36% | +19.35% | +14.01% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth | 6,293.1 | +1.81% | +9.15% | +16.35% | +6.18% | +23.07% | +15.99% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth | 6,293.1 | +1.88% | +9.37% | +16.82% | +7.07% | +24.11% | +17.02% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw | 6,293.1 | +1.88% | +9.37% | +16.82% | +7.07% | +24.11% | +17.02% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw | 6,293.1 | +1.81% | +9.15% | +16.35% | +6.18% | +23.07% | +15.99% |
Top funds are based on Fund AUM
Top Equity Funds
| Fund name | ||||
|---|---|---|---|---|
| Sbi Healthcare Opportunities Fund Direct Plan-growth | ₹585.48 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-growth | ₹585.48 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-idcw | ₹406.78 | +23.82% | +18.25% | — |
| Sbi Healthcare Opportunities Fund Direct Plan-idcw | ₹406.78 | +23.82% | +18.25% | — |
| Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth | ₹47.15 | +24.11% | +17.02% | — |
| Icici Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw | ₹28.47 | +24.11% | +17.02% | — |
| Sbi Healthcare Opportunities Fund-growth | ₹506.05 | +22.55% | +17.02% | — |
| Sbi Healthcare Opportunities Fund-idcw | ₹318.78 | +22.55% | +17.02% | — |
| Mirae Asset Healthcare Fund Direct-growth | ₹50.72 | +23.36% | +16.17% | — |
| Mirae Asset Healthcare Fund Direct-idcw | ₹30.55 | +23.36% | +16.17% | — |
growth is based on 5Y returns of the funds
Historical NAV
| Date | NAV |
|---|---|
| 27 Jul 2026 | ₹563.86 |
| 24 Jul 2026 | ₹556.11 |
| 23 Jul 2026 | ₹557.34 |
| 22 Jul 2026 | ₹559.54 |
| 21 Jul 2026 | ₹568.78 |
| 20 Jul 2026 | ₹566.84 |
| 17 Jul 2026 | ₹560.96 |
| 16 Jul 2026 | ₹567.35 |
| 15 Jul 2026 | ₹566.06 |
| 14 Jul 2026 | ₹564.60 |
| 13 Jul 2026 | ₹561.02 |
| 10 Jul 2026 | ₹562.29 |
| 09 Jul 2026 | ₹560.38 |
| 08 Jul 2026 | ₹555.48 |
| 07 Jul 2026 | ₹561.81 |
| 06 Jul 2026 | ₹564.84 |
| 03 Jul 2026 | ₹564.22 |
| 02 Jul 2026 | ₹557.50 |
| 01 Jul 2026 | ₹555.04 |
| 30 Jun 2026 | ₹557.42 |
| 29 Jun 2026 | ₹553.38 |
| 25 Jun 2026 | ₹550.82 |
| 24 Jun 2026 | ₹551.86 |
| 23 Jun 2026 | ₹550.01 |
| 22 Jun 2026 | ₹547.20 |
| 19 Jun 2026 | ₹542.66 |
| 18 Jun 2026 | ₹539.46 |
| 17 Jun 2026 | ₹535.25 |
| 15 Jun 2026 | ₹536.29 |
| 12 Jun 2026 | ₹538.56 |
Portfolio Updated on: 28 Jul, 2026
Fund Growth & Size Analysis
+₹7,898.2 Cr
Since Launch
This Fund
Category Average
Compare Mutual funds
Nippon India Pharma Fund-growth Returns Comparison
Compare Nippon India Pharma Fund-growth with any MF,
EYF, stock or index
Jan 1, 2026 – Feb 1, 2026
Nippon India Pharma Fu....
No funds found for your search.
Nippon India Pharma Fund-growth FAQ'S
- Sharpe Ratio: 0.96%
- Standard Deviation: 15.71%
- Beta: 0.91%
- Alpha: -0.98%
Additional important ratios:
As of Tue Mar 31, 2026, the total assets managed under Nippon India Pharma Fund-growth stand at approximately ₹ 7,898.2 crore.
The Nippon India Pharma Fund-growth has delivered the following short-term performance:
- 3 Months Return: 8.92%
- 6 Months Return: 15.97%
The historical growth of the Nippon India Pharma Fund-growth is reflected through its CAGR returns:
- 3 Year CAGR: 18.28%
- 5 Year CAGR: 12.99%
- Return Since Launch: 19.96%
The portfolio of Nippon India Pharma Fund-growth is distributed across different asset classes as follows:
- Equity: 97.64%
- Debt Instruments: 0.01%
- Other Assets: 2.35%
The Nippon India Pharma Fund-growth is managed by Sailesh Raj Bhan, representing Nippon India Mutual Fund.
The Nippon India Pharma Fund-growth investments are allocated across market caps in the following manner:
- Large Cap Stocks: 1.00%
- Mid Cap Stocks: 1.00%
- Small Cap Stocks: 1.00%
Top stock holdings of Nippon India Pharma Fund-growth include:
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 1.00% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.55% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.92% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.08% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 13.02% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 12.67% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 12.67% of the portfolio
- Sun Pharmaceutical Industries Ltd – represents 12.67% of the portfolio
Major sector exposures in Nippon India Pharma Fund-growth are:
- Healthcare – accounts for 996.17% of the portfolio
